Kythera Biopharmaceuticals ( KYTH) and Intercept Pharmaceuticals ( ICPT) are two biotechs with big market opportunities and, in the case of Intercept, also have orphan drug protection. Shutterstock ( SSTK) is one of only a few players in its space, said Cramer, while Fleetmatics ( FLTX) is another cloud play like Workday. Compare those successful IPOs to those of two weeks ago, however, and the stories change. Berry Plastics ( BERY) is a commodity plastic container maker with next to no growth. Lifelock ( LOCK) provides identity protection but is seeing increased competition and is not yet profitable. Javelin Mortgage ( JMI) aims to be a REIT, but has no track record to offer investors, while Regulus Therapeutics ( RGLS) is a biotech with no funding. Cramer said its easy to see why this second group of IPOs failed to impress Wall Street.